Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke

Withdrawn

Phase 1/2 Results N/A

Summary of Purpose

Stroke is a major cause of adult disability. Currently approved reperfusion therapies are provided to only a small percentage of patients in the U.S. New therapies are needed that improve outcome and that can be accessed by a majority of patients. Animal studies suggest that bone marrow-derived mesenchymal stem cells,... Trial Stopped: Study was never started

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 20 January 2016.

1 Jan 2016 6 May 2013 1 Jan 2016 1 Jan 2016 1 Jan 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Contacts

  • Steven C. Cramer, MD, MMSc